Clinical Scorecard: Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease |
| Key Mechanisms | Cross-linked hyaluronic acid gel occludes the canalicular system to enhance tear film preservation. |
| Target Population | Patients with dry eye disease, particularly those undergoing ocular surgical procedures. |
| Care Setting | Healthcare professionals' offices across Europe. |
Key Highlights
- Lacrifill® provides long-lasting effects for up to six months.
- Designed to temporarily block tear drainage for improved ocular surface lubrication.
- Addresses challenges in patients with pre-existing ocular surface disease.
Guideline-Based Recommendations
Diagnosis
- Assess ocular surface health in patients with dry eye disease.
Management
- Utilize Lacrifill® for pre-and post-operative ocular surface health optimization.
Monitoring & Follow-up
- Monitor tear film stability and patient satisfaction post-application.
Risks
- Consider potential complications related to ocular surgery in patients with dry eye.
Patient & Prescribing Data
Patients with dry eye disease, especially those preparing for cataract or LASIK surgery.
Lacrifill® offers an individualized approach to managing dry eye symptoms.
Clinical Best Practices
- Incorporate Lacrifill® into treatment plans for patients with dry eye disease.
- Educate patients on the benefits of maintaining a stable ocular surface.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
